Niquitin Minizuigtablet (Nicotine)

Nicotine in Niquitin Minizuigtablet binds to nicotinic acetylcholine receptors in the brain, stimulating dopamine release. This mimics the effect of smoking, easing withdrawal and decreasing the urge to smoke while the user works toward complete cessation.

The specific dose and dosing schedule are determined by the prescribing clinician based on the individual’s smoking history, dependence level, and medical condition. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for nicotine replacement therapy during pregnancy and lactation are limited. Healthcare providers should weigh the potential risks and benefits before prescribing it to pregnant or nursing individuals, and alternative cessation strategies may be considered.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Niquitin Minizuigtablet delivers nicotine via an oromucosal tablet, offering a discreet, non‑inhaled route. Compared with patches, gums, or lozenges, tablets may provide more precise dosing and faster onset, but choice depends on patient preference, tolerance, and clinical judgment.

Store the tablets at ambient temperature below 25 °C, in their original packaging, and protect them from moisture and direct sunlight. Keep out of reach of children and do not use if the packaging is damaged.

The tablet is placed in the mouth and allowed to dissolve on the oral mucosa, where nicotine is absorbed through the lining. Patients should avoid swallowing whole tablets and follow the prescriber’s instructions for frequency and timing.

Serious risks include severe allergic reactions such as anaphylaxis, cardiovascular events like chest pain or arrhythmias, and rare skin conditions such as Stevens‑Johnson syndrome. Users should seek immediate medical attention if any of these symptoms occur.

Individuals with known hypersensitivity to nicotine, recent myocardial infarction, uncontrolled hypertension, or those already using other nicotine replacement products without medical supervision should avoid this tablet. A healthcare professional should evaluate suitability before prescribing.